Background: The benefit-risk profile of direct oral anticoagulants (DOACs) compared with
warfarin, and between DOACs in patients with atrial fibrillation (AF) and chronic liver disease …

Background Liver disease is associated with increased bleeding risk. The efficacy and
safety of direct oral anticoagulants (DOACs) is a subject of contention in atrial fibrillation (AF) …

Background and aims The effects of direct oral anticoagulants (DOACs) in patients with non-
valvular atrial fibrillation (NVAF) and liver disease remain poorly understood. Our …

Background: Advanced liver disease is known to increase the risk for bleeding and affects
the hepatic clearance and metabolism of drugs. Subjects with active liver disease were …

Direct oral anticoagulants (DOACs) have had a positive impact in preventing cardioembolic
stroke in patients with atrial fibrillation (AF) who were associated with lower bleeding …

Background Patients with atrial fibrillation (AF) have a higher risk of developing
thromboembolic events. Current guidelines recommend the use of oral anticoagulants for …

Background The effect of non-vitamin K antagonist oral anticoagulants (NOACs) in patients
with atrial fibrillation (AF) and liver disease remains largely unresolved. Therefore, we …

Objective To assess the risk of liver injury hospitalisation in patients with atrial fibrillation
(AF) after initiation of direct oral anticoagulants (DOACs) or warfarin and to determine …

Background Many patients with cirrhosis have concurrent nonvalvular atrial fibrillation
(NVAF). Data are lacking regarding recent oral anticoagulant (OAC) usage trends among …

Abstract Background Direct oral anticoagulants (DOACs) are recommended for stroke
prevention in patients with atrial fibrillation (AF) or for treatment of deep vein thrombosis …